AcelRx To Present At Two Upcoming Investor Conferences In June

REDWOOD CITY, Calif., May 22, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that interim chief executive officer Howie Rosen will be presenting at Jefferies 2015 Healthcare Conference and chief financial officer Tim Morris will be presenting at JMP Securities Life Science Conference. Details of the two presentations are as follows:

Jefferies 2015 Healthcare Conference
Date: Monday June 1
Location: Grand Hyatt, New York
Presentation Time: 4:00 pm ET, 1:00 pm PT

JMP Securities Life Science Conference
Date:  Wednesday June 24
Location: The St. Regis New York
Presentation Time: 9:00 am ET, 6:00 am PT

Presentations will be webcast live and can be accessed through the Investors page at www.acelrx.com.  For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.
AcelRx's lead product candidate, Zalviso, is designed to improve the management of moderate-to-severe acute pain in adult patients in the hospital setting by utilizing a high therapeutic index opioid, through a non-invasive delivery route via a pre-programmed, patient-controlled analgesia device. AcelRx has announced positive results from each of the three completed Phase 3 clinical trials for Zalviso, has submitted an NDA to the FDA seeking approval for Zalviso in the treatment of moderate-to-severe acute pain in adult patients in the hospital setting and on July 25, 2014, received a Complete Response Letter (CRL) from the FDA. In March 2015, AcelRx received correspondence from the FDA stating that in addition to the bench testing and two Human Factors studies AcelRx has performed to address dispensing issues raised in the CRL, an additional clinical trial is needed to assess the risk of inadvertent dispensing and overall risk of dispensing failures. AcelRx has submitted a formal meeting request to the FDA and this request has been denied and AcelRx is evaluating its next steps with regards to the regulatory process for Zalviso. In March 2015, AcelRx initiated SAP301, a pivotal Phase 3 study for ARX-04, a product candidate for the treatment of moderate-to-severe acute pain in a medically supervised setting. SAP301 is now actively enrolling. The Company has two additional pain treatment product candidates, ARX-02 and ARX-03, which have completed Phase 2 clinical development. For additional information about AcelRx's clinical programs, please visit www.acelrx.com.

Logo - http://photos.prnewswire.com/prnh/20130226/MM67303LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-two-upcoming-investor-conferences-in-june-300087679.html

SOURCE AcelRx Pharmaceuticals, Inc.